Ibrutinib is a medicine used to treat some blood cancers, like chronic lymphocytic leukemia, and a problem that can happen after a stem cell transplant. It is taken by mouth as a capsule, tablet or liquid. It works by blocking a protein called BTK that cancer cells need to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Imbruvica (Ibrutinib) for CLL (Chronic Lymphocytic Leukemia)?
Ibrutinib, sold as Imbruvica, is a targeted cancer medicine taken by mouth. In adults it treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), which are two forms of the same slow-growing cancer of B cells, a type of white blood cell. That includes CLL with a 17p deletion, a genetic change that makes the disease respond poorly to standard chemotherapy. It also treats Waldenström's macroglobulinemia, a rare B-cell cancer that tends to build up in the bone marrow and produce an abnormal antibody. Ibrutinib has a separate use after a stem cell or bone marrow transplant. It treats chronic graft-versus-host disease (GVHD), in which immune cells from the donor attack the recipient's skin, mouth, eyes, liver or other organs, in adults and children aged 1 and older once at least one other whole-body treatment has failed. Ibrutinib was the first of the Bruton's tyrosine kinase (BTK) inhibitors, drugs that block a signal B cells need to grow. Two newer ones, acalabrutinib (Calquence) and zanubrutinib (Brukinsa), caused fewer irregular heart rhythms than ibrutinib when the drugs were compared directly in people with previously treated CLL, and in that setting zanubrutinib also kept the disease under control longer. That is one reason specialists now often choose a newer BTK inhibitor, although ibrutinib remains an approved option.
B cells rely on signals from a receptor on their surface to survive, multiply and settle in places such as the lymph nodes and bone marrow. BTK is an enzyme that relays those signals inside the cell. In CLL and related cancers, the cancerous B cells depend heavily on this pathway. Ibrutinib binds permanently to BTK and switches it off. Without that signal, cancer cells grow and survive less well and have trouble staying anchored in the lymph nodes and marrow. Ibrutinib controls these cancers rather than curing them, which is why it is taken continuously. In chronic GVHD, the same effect dampens the overactive donor immune cells driving the reaction.
Ibrutinib comes as capsules, tablets and a liquid suspension. It is taken once a day, at about the same time each day. For CLL, SLL and Waldenström's, adults usually take a single daily dose, either alone or alongside an antibody treatment such as rituximab. Children with chronic GVHD get a dose based on their body size, often as the liquid. Swallow capsules and tablets whole with a glass of water. Do not open, cut, crush or chew them. If a dose is missed, take it as soon as possible the same day and go back to the usual schedule the next day; never take extra to make up for it. The dose is often lowered for side effects, for liver problems, or when another medicine raises ibrutinib levels in the blood, so follow the current prescription rather than an earlier one.
Diarrhea, tiredness, muscle and joint aches, rash, nausea and easy bruising are among the most common side effects. Diarrhea often settles, but tell the care team if it continues, and drink enough fluids. Ibrutinib also commonly lowers blood counts, which is why regular blood tests are part of treatment. Several serious effects need prompt attention. Ibrutinib can cause irregular heart rhythms, especially atrial fibrillation, and less often heart failure or sudden death. People with high blood pressure, diabetes or existing heart disease are at higher risk. Report palpitations, dizziness, shortness of breath, swollen legs or chest discomfort right away. Chest pain, fainting or bleeding that will not stop needs emergency care. Bleeding problems range from minor bruising to rare serious bleeding in the gut or brain. Call the care team right away for blood in the urine or stool, bleeding that lasts longer than usual, or a severe headache. Serious infections, including pneumonia, are also more likely, so report fever, chills or new confusion promptly. Liver injury is uncommon but can be serious; dark urine, yellowing skin or eyes, or new belly pain should be reported right away. High blood pressure is common and can develop months or years into treatment. Other cancers, mostly non-melanoma skin cancers, have occurred in people taking ibrutinib, so regular skin checks are worthwhile.
Ibrutinib increases bleeding risk on its own, and more so alongside blood thinners such as warfarin or apixaban, and antiplatelet drugs such as aspirin or clopidogrel. If one of these is needed, the prescriber weighs the combined risk. Tell every surgeon and dentist about ibrutinib, because it is usually paused for several days before and after surgery or dental work. Ibrutinib is broken down by a liver enzyme called CYP3A. Medicines that block this enzyme raise ibrutinib levels and side effects, including the antifungals voriconazole and posaconazole and some antibiotics; a short antibiotic course may mean pausing ibrutinib for a few days. Other medicines speed the enzyme up and can make ibrutinib less effective. Avoid grapefruit and Seville oranges, including marmalade and juice, which block the same enzyme. Check with a pharmacist before starting any new medicine, supplement or herbal product. Ibrutinib can harm a developing baby. People who could become pregnant should use effective contraception during treatment and for 1 month after the last dose, and men with partners who could become pregnant should also use contraception for that period. Do not breastfeed during treatment or for 1 week after stopping.
Ibrutinib is usually a long-term, ongoing treatment. For CLL, SLL and Waldenström's it is taken every day for as long as it keeps the disease under control and side effects remain manageable, which for many people means years. For chronic GVHD, it continues until the condition no longer needs treatment or stops responding. Before starting, the care team checks the heart, blood pressure, blood counts and liver tests. Blood counts are typically checked monthly, with regular blood pressure and liver checks throughout. Anyone who develops palpitations or breathlessness may have an electrocardiogram (ECG), a quick test of the heart's electrical rhythm, or a heart ultrasound. If a side effect becomes a problem, the usual first step is a pause and then a lower dose, rather than stopping for good. Many people who cannot tolerate ibrutinib switch to a newer BTK inhibitor or a different type of treatment and continue to do well. Because the drug controls rather than cures these cancers, stopping it without a plan can allow the disease to return.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Imbruvica (Ibrutinib), what you've noticed, or ask the community a question.